Wednesday, July 8, 2026

biotech · Lupus Nephritis - WHO Class III · Non Hodgkin Lymphoma · ARTV

Artiva Biotherapeutics

Artiva Biotherapeutics clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

San Diego, USA HQ
2019 Founded
105 Employees
Public company Type
ARTV · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2019
Employees
105
Programs
8
Drugs
9
Patents
0
Intelligence · Clinical Programs

Artiva Biotherapeutics projects

3 ClinicalTrials.gov programs sponsored by Artiva Biotherapeutics.

Artiva Biotherapeutics has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AB-101

    Artiva Biotherapeutics

    Lupus Nephritis - WHO Class III

    phase 1 small molecule active

    1 trial
  2. AB-101

    Artiva Biotherapeutics

    Rheumatoid Arthritis

    phase 1 small molecule active

    1 trial
  3. GCC2005

    Artiva Biotherapeutics

    Lymphoma, T-Cell

    phase 1 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Artiva Biotherapeutics have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.